Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

Inclusion Criteria: * Participant has provided informed consent prior to initiation of any study specific activities/procedures * Male or female ≥ 18 years of age at time of enrollment and willing and able to provide informed consent * Histologically confirmed non-squamous NSCLC performed within 90 days of enrollment with EGFR Ex20Ins-mutated (addition of 1 or more amino acids) or uncommon/compound EGFR mutations (E709X, G719X, L747X, S758I, and/or L861Q) in tumor tissue or blood; any one of these mutations would qualify if compounded with another EGFR mutation * Staging positron emission tomography-computed tomography (PET-CT) and brain magnetic resonance imaging (MRI) within 60 days of enrollment demonstrating stage II, IIIA, or IIIB (N2) NSCLC (American Joint Commission for Cancer \[AJCC\] version \[v\] 9); mediastinal staging is required by bronchoscopy or mediastinoscopy * No prior systemic treatment for lung cancer * Resectable and operable as determined by thoracic surgeon * At least one measurable lesion according to Response Evaluation Criteira in Solid Tumors (RECIST) 1.1. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Absolute neutrophil count (ANC) ≥ 1.0 x 10\^9/L * Platelets ≥ 100 x 10\^9/L * Hemoglobin ≥ 9 g/dL without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) * Glomerular filtration rate (GFR; by Cockroft-Gault or equivalent estimation) ≥ 45 mL/min/1.73 m\^2 * Serum total bilirubin ≤ 1.5 x upper li…